Temporary Associate, DEL Screening

Location
San Francisco, CA, United States
Posted
May 29, 2021
Ref
5235420002
Hotbed
Biotech Bay
Required Education
Bachelors Degree
Position Type
Full time

Position

We are seeking a researcher who is interested in working with scientists in our DNA-encoded chemical library (DEL) screening team to perform assays in support of our drug discovery process. This work includes performing qPCR assays, Illumina next-generation sequencing (NGS) templates, and other molecular biology, protein biochemistry, and analytical biochemistry duties.

Required Qualifications

The candidate we seek must have a degree in the life sciences with a strong background in biochemistry and molecular biology. Moreover, we are interested in someone who integrates well within a process-oriented team. The successful candidate should have very good organizational and communication skills.

 

  • Experience: Two or more years of industry experience performing qPCR assays and preparing NGS sequencing samples
  • Specific Technical Proficiency in: qPCR assay (absolute method), PCR amplification reactions, DNA and protein quantitation, workflows involving multi-channel pipetting
  • Instrument Proficiency Desired: Real-time PCR instrumentation (QuantStudio7, Bio-Rad CFX384, etc.), Agilent TapeStation or Bioanalyzer, Nanodrop spectrophotometer, various plate readers, liquid chromatography-mass spectrometry a plus
  • Software Proficiency Required: Excel, Word, PowerPoint


Fit with Nurix Culture and Values

 

 

  • Strong team orientation; highly collaborative
  • Solutions and results-oriented focus
  • Hands-on approach; resourceful and open to diverse points of view


Company

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.